Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event Compared to Placebo – – NEXLETOL Demonstrated Clinical Benefit in...
Alexis Callahan Tiffany Aldrich Leslie Cho Joanne Foody Fatima Rodriguez Journal Of The American College Cardiology
Source: marketscreener.com